Acura logo.jpg
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
March 01, 2022 06:30 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”)...
Acura logo.jpg
Acura Pharmaceuticals Provides Development Update on LTX-03
February 14, 2022 06:30 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx...
Acura logo.jpg
Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results
November 15, 2021 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of...
Acura logo.jpg
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results
August 16, 2021 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of...
Acura logo.jpg
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
July 26, 2021 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”)...
Acura logo.jpg
Acura Pharmaceuticals Announces Conversion of Debt
June 14, 2021 16:10 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., June 14, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that Abuse Deterrent Pharma, LLC (“AD Pharma”) has converted the entire principle and...
Acura logo.jpg
Acura Pharmaceuticals Provides Development Update on LTX-03
June 07, 2021 06:00 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., June 07, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced the successful completion of three NDA required registration batches of the to-be-marketed...
Acura logo.jpg
Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results
May 17, 2021 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of...
Acura logo.jpg
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
March 31, 2021 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., March 31, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of...
Acura logo.jpg
Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results
November 16, 2020 16:15 ET | Acura Pharmaceuticals, Inc.
PALATINE, Ill., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of...